We are live on ! Find out more
ENTX icon

Entera Bio

6 hedge funds and large institutions have $3.1M invested in Entera Bio in 2018 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

50% more funds holding

Funds holding: 46 (+2)

2.25% more ownership

Funds ownership: 6.72%8.98% (+2.3%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

25% less capital invested

Capital invested by funds: $4.11M → $3.1M (-$1.01M)

Holders
6
Holders Change
+2
Holders Change %
+50%
% of All Funds
0.13%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
3
Increased
2
Reduced
Closed
1
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
KCM
1
Knoll Capital Management
Florida
$1.45M
DAM
2
DLD Asset Management
New York
$931K +$124K +25,014 +9%
WCM
3
Wildcat Capital Management
New York
$620K +$1.01M +203,190 New
WVP
4
Worth Venture Partners
New Jersey
$53K +$71.3K +14,339 +114%
FIA
5
FNY Investment Advisers
New York
$46K +$75.6K +15,189 New
UBS Group
6
UBS Group
Switzerland
-$2K -365 Closed
TRCT
7
Tower Research Capital (TRC)
New York
+$10 +2 New

ENTX Hedge Fund Activity: Q4 2018 in Review

6 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Entera Bio (ENTX) for Q4 2018, worth a combined $3.1M — down 25% from $4.11M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ENTX positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Wildcat Capital Management, opening a new position worth an estimated $1.01M. The largest seller was UBS Group, exiting entirely with an estimated $2K sold.

  • 6 institutional investors held Entera Bio (ENTX) as of Q4 2018, up from 4 in Q3 2018.
  • Funds reported $3.1M of Entera Bio stock for Q4 2018, down 25% quarter-over-quarter.
  • 3 funds opened new Entera Bio positions in Q4 2018 and 1 closed out, a net change of +2 holders.
  • The largest Entera Bio buyer in Q4 2018 was Wildcat Capital Management, an estimated $1.01M added.
  • The largest Entera Bio seller in Q4 2018 was UBS Group, an estimated $2K sold.

Based on aggregated 13F filings for Q4 2018.